Oncogenic role of kinesin proteins and targeting kinesin therapy

Cancer Science

Volumn 104, Issue 6, 2013, Pages 651-656

  Liu, Xinran ^a   Gong, Hao ^a   Huang, Kun ^a,b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Wuhan Institute of Biotechnology   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4SC 205; ADENOSINE TRIPHOSPHATASE; ANTINEOPLASTIC AGENT; ARQ 621; ARRY 520; AZD 4877; GSK 923295; ISPINESIB; KINESIN; KINESIN 1; KINESIN 10; KINESIN 11; KINESIN 14; KINESIN 1B; KINESIN 2; KINESIN 20A; KINESIN 20B; KINESIN 23; KINESIN 2A; KINESIN 3A; KINESIN 3B; KINESIN 4; KINESIN 4A; KINESIN 5; KINESIN 5B; KINESIN 7; LITRONESIB; MK 0731; SB 743921; UNCLASSIFIED DRUG;

ANEMIA; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; COLORECTAL CANCER; DISEASE COURSE; DISEASE FREE SURVIVAL; DOWN REGULATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GLIOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPERBILIRUBINEMIA; HYPONATREMIA; KIDNEY CARCINOMA; LEUKOPENIA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MELANOMA; MICROTUBULE; MITOSIS; MONOTHERAPY; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINOBLASTOMA; REVIEW; SIDE EFFECT; STOMACH CARCINOMA; UPREGULATION; UTERINE CERVIX CANCER;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; KINESIN;

EID: 84878194756     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12138     Document Type: Review

References (81)

1. Vale RD, Reese TS, Sheetz MP. Identification of a novel force-generating protein, kinesin, involved in microtubule-based motility. Cell 1985; 42: 39-50.
2. Lawrence CJ, Dawe RK, Christie KR et al. A standardized kinesin nomenclature. J Cell Biol 2004; 167: 19-22.
3. Miki H, Setou M, Kaneshiro K, Hirokawa N. All kinesin superfamily protein, KIF, genes in mouse and human. Proc Natl Acad Sci USA 2001; 98: 7004-11.
4. Diefenbach RJ, Mackay JP, Armati PJ, Cunningham AL. The C-terminal region of the stalk domain of ubiquitous human kinesin heavy chain contains the binding site for kinesin light chain. Biochemistry 1998; 37: 16663-70.
5. Goldstein LS, Philp AV. The road less traveled: emerging principles of kinesin motor utilization. Annu Rev Cell Dev Biol 1999; 15: 141-83.
6. Castillo A, Morse HC 3rd, Godfrey VL, Naeem R, Justice MJ. Overexpression of Eg5 causes genomic instability and tumor formation in mice. Cancer Res 2007; 67: 10138-47.
7. Wordeman L. How kinesin motor proteins drive mitotic spindle function: lessons from molecular assays. Semin Cell Dev Biol 2010; 21: 260-8.
8. Oki E, Hisamatsu Y, Ando K, Saeki H, Kakeji Y, Maehara Y. Clinical aspect and molecular mechanism of DNA aneuploidy in gastric cancers. J Gastroenterol 2012; 47: 351-8.
9. Liu XR, Cai Y, Cao X et al. A new oncolytic adenoviral vector carrying dual tumour suppressor genes shows potent anti-tumour effect. J Cell Mol Med 2012; 16: 1298-309.
10. Dyrskjot L, Kruhoffer M, Thykjaer T et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 2004; 64: 4040-8.
11. Richardson AL, Wang ZC, de Nicolo A et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 2006; 9: 121-32.
12. Jimbo T, Kawasaki Y, Koyama R et al. Identification of a link between the tumour suppressor APC and the kinesin superfamily. Nat Cell Biol 2002; 4: 323-7.
13. Lukong KE, Richard S. Breast tumor kinase BRK requires kinesin-2 subunit KAP3A in modulation of cell migration. Cell Signal 2008; 20: 432-42.
14. Yeh IT, Lenci RE, Qin Y et al. A germline mutation of the KIF1B beta gene on 1p36 in a family with neural and nonneural tumors. Hum Genet 2008; 124: 279-85.
15. Corson TW, Gallie BL. KIF14 mRNA expression is a predictor of grade and outcome in breast cancer. Int J Cancer 2006; 119: 1088-94.
16. Corson TW, Zhu CQ, Lau SK, Shepherd FA, Tsao MS, Gallie BL. KIF14 messenger RNA expression is independently prognostic for outcome in lung cancer. Clin Cancer Res 2007; 13: 3229-34.
17. Corson TW, Huang A, Tsao MS, Gallie BL. KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers. Oncogene 2005; 24: 4741-53.
18. Taniwaki M, Takano A, Ishikawa N et al. Activation of KIF4A as a prognostic biomarker and therapeutic target for lung cancer. Clin Cancer Res 2007; 13: 6624-31.
19. Narayan G, Bourdon V, Chaganti S et al. Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes. Genes Chromosom Cancer 2007; 46: 373-84.
20. Tremblay MR, Lescarbeau A, Grogan MJ et al. Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). J Med Chem 2009; 52: 4400-18.
21. Sarangi A, Valadez JG, Rush S, Abel TW, Thompson RC, Cooper MK. Targeted inhibition of the Hedgehog pathway in established malignant glioma xenografts enhances survival. Oncogene 2009; 28: 3468-76.
22. Kanehira M, Katagiri T, Shimo A et al. Oncogenic role of MPHOSPH1, a cancer-testis antigen specific to human bladder cancer. Cancer Res 2007; 67: 3276-85.
23. Takahashi S, Fusaki N, Ohta S et al. Downregulation of KIF23 suppresses glioma proliferation. J Neurooncol 2012; 106: 519-29.
24. Taniuchi K, Nakagawa H, Nakamura T et al. Down-regulation of RAB6KIFL/KIF20A, a kinesin involved with membrane trafficking of discs large homologue 5, can attenuate growth of pancreatic cancer cell. Cancer Res 2005; 65: 105-12.
25. Yan GR, Zou FY, Dang BL et al. Genistein-induced mitotic arrest of gastric cancer cells by downregulating KIF20A, a proteomics study. Proteomics 2012; 12: 2391-9.
26. Schafer-Hales K, Iaconelli J, Snyder JP et al. Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function. Mol Cancer Ther 2007; 6: 1317-28.
27. Bie L, Zhao G, Wang YP, Zhang B. Kinesin family member 2C (KIF2C/MCAK) is a novel marker for prognosis in human gliomas. Clin Neurol Neurosurg 2012; 114: 356-60.
28. Ishikawa K, Kamohara Y, Tanaka F et al. Mitotic centromere-associated kinesin is a novel marker for prognosis and lymph node metastasis in colorectal cancer. Br J Cancer 2008; 98: 1824-9.
29. Ganguly A, Yang H, Cabral F. Overexpression of mitotic centromere-associated kinesin stimulates microtubule detachment and confers resistance to paclitaxel. Mol Cancer Ther 2011; 10: 929-37.
30. Wang CQ, Qu X, Zhang XY et al. Overexpression of Kif2a promotes the progression and metastasis of squamous cell carcinoma of the oral tongue. Oral Oncol 2010; 46: 65-9.
31. Grinberg-Rashi H, Ofek E, Perelman M et al. The expression of three genes in primary non-small cell lung cancer is associated with metastatic spread to the brain. Clin Cancer Res 2009; 15: 1755-61.
32. De S Cipriano R, Cipriano R, Jackson MW, Stark GR. Overexpression of kinesins mediates docetaxel resistance in breast cancer cells. Cancer Res 2009; 69: 8035-42.
33. Rouam S, Moreau T, Broet P. Identifying common prognostic factors in genomic cancer studies: a novel index for censored outcomes. BMC Bioinformatics 2010; 11: 150.
34. Gao J, Sai N, Wang C et al. Overexpression of chromokinesin KIF4 inhibits proliferation of human gastric carcinoma cells both in vitro and in vivo. Tumour Biol 2011; 32: 53-61.
35. Mazumdar M, Lee JH, Sengupta K, Ried T, Rane S, Misteli T. Tumor formation via loss of a molecular motor protein. Curr Biol 2006; 16: 1559-64.
36. Madhavan J, Coral K, Mallikarjuna K et al. High expression of KIF14 in retinoblastoma: association with older age at diagnosis. Invest Ophthalmol Vis Sci 2007; 48: 4901-6.
37. Maney T, Hunter AW, Wagenbach M, Wordeman L. Mitotic centromere-associated kinesin is important for anaphase chromosome segregation. J Cell Biol 1998; 142: 787-801.
38. Sanhaji M, Friel CT, Wordeman L, Louwen F, Yuan J. Mitotic centromere-associated kinesin (MCAK): a potential cancer drug target. Oncotarget 2011; 2: 935-47.
39. Nishidate T, Katagiri T, Lin ML et al. Genome-wide gene-expression profiles of breast-cancer cells purified with laser microbeam microdissection: identification of genes associated with progression and metastasis. Int J Oncol 2004; 25: 797-819.
40. Shimo A, Tanikawa C, Nishidate T et al. Involvement of kinesin family member 2C/mitotic centromere-associated kinesin overexpression in mammary carcinogenesis. Cancer Sci 2008; 99: 62-70.
41. Gnjatic S, Cao Y, Reichelt U et al. NY-CO-58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer. Int J Cancer 2010; 127: 381-93.
42. Nakamura Y, Tanaka F, Haraguchi N et al. Clinicopathological and biological significance of mitotic centromere-associated kinesin overexpression in human gastric cancer. Br J Cancer 2007; 97: 543-9.
43. Nagase H, Nakamura Y. Mutations of the APC (adenomatous polyposis coli) gene. Hum Mutat 1993; 2: 425-34.
44. Komarova Y, de Groot CO, Grigoriev I et al. Mammalian end binding proteins control persistent microtubule growth. J Cell Biol 2009; 184: 691-706.
45. Moore AT, Rankin KE, von Dassow G et al. MCAK associates with the tips of polymerizing microtubules. J Cell Biol 2005; 169: 391-7.
46. Lee T, Langford KJ, Askham JM, Bruning-Richardson A, Morrison EE. MCAK associates with EB1. Oncogene 2008; 27: 2494-500.
47. Ganem NJ, Compton DA. The KinI kinesin Kif2a is required for bipolar spindle assembly through a functional relationship with MCAK. J Cell Biol 2004; 166: 473-8.
48. Li G, Luna C, Qiu J, Epstein DL, Gonzalez P. Targeting of integrin beta1 and kinesin 2alpha by microRNA 183. J Biol Chem 2010; 285: 5461-71.
49. Theriault BL, Pajovic S, Bernardini MQ, Shaw PA, Gallie BL. Kinesin family member 14: an independent prognostic marker and potential therapeutic target for ovarian cancer. Int J Cancer 2012; 130: 1844-54.
50. Abiatari I, DeOliveira T, Kerkadze V et al. Consensus transcriptome signature of perineural invasion in pancreatic carcinoma. Mol Cancer Ther 2009; 8: 1494-504.
51. Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 2010; 10: 194-204.
52. Zelnak A. Overcoming taxane and anthracycline resistance. Breast J 2010; 16: 309-12.
53. Morris PG, Fornier MN. Microtubule active agents: beyond the taxane frontier. Clin Cancer Res 2008; 14: 7167-72.
54. Tan MH, De S, Bebek G et al. Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer. Breast Cancer Res Treat 2012; 131: 849-58.
55. Sawin KE, LeGuellec K, Philippe M, Mitchison TJ. Mitotic spindle organization by a plus-end-directed microtubule motor. Nature 1992; 359: 540-3.
56. Sarli V, Giannis A. Targeting the kinesin spindle protein: basic principles and clinical implications. Clin Cancer Res 2008; 14: 7583-7.
57. Blangy A, Lane HA, d'Herin P, Harper M, Kress M, Nigg EA. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 1995; 83: 1159-69.
58. Weil D, Garcon L, Harper M, Dumenil D, Dautry F, Kress M. Targeting the kinesin Eg5 to monitor siRNA transfection in mammalian cells. Biotechniques 2002; 33: 1244-8.
59. Mayer TU, Kapoor TM, Haggarty SJ, King RW, Schreiber SL, Mitchison TJ. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 1999; 286: 971-4.
60. Huszar D, Theoclitou ME, Skolnik J, Herbst R. Kinesin motor proteins as targets for cancer therapy. Cancer Metastasis Rev 2009; 28: 197-208.
61. Sakowicz R, Finer JT, Beraud C et al. Antitumor activity of a kinesin inhibitor. Cancer Res 2004; 64: 3276-80.
62. Blagden SP, Molife LR, Seebaran A et al. A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours. Br J Cancer 2008; 98: 894-9.
63. Knox JJ, Gill S, Synold TW et al. A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). Invest New Drugs 2008; 26: 265-72.
64. Tang PA, Siu LL, Chen EX et al. Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. Invest New Drugs 2008; 26: 257-64.
65. Lee CW, Belanger K, Rao SC et al. A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs 2008; 26: 249-55.
66. Kantarjian HM, Padmanabhan S, Stock W et al. Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia. Invest New Drugs 2012; 30: 1107-15.
67. Holen KD, Belani CP, Wilding G et al. A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose. Cancer Chemother Pharmacol 2011; 67: 447-54.
68. Gerecitano JF, Stephenson JJ, Lewis NL et al. A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies. Invest New Drugs 2013; 31: 355-62.
69. Holen K, DiPaola R, Liu G et al. A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors. Invest New Drugs 2012; 30: 1088-95.
70. Khoury HJ, Garcia-Manero G, Borthakur G et al. A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias. Cancer 2012; 118: 3556-64.
71. Common Terminology Criteria for Adverse Events (version 3): Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. March 31, 2003. [Published 09 Aug 2006.] Available from URL: http://ctep.cancer.gov.
72. Gomez HL, Philco M, Pimentel P et al. Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer. Anticancer Drugs 2012; 23: 335-41.
73. Chung V, Heath EI, Schelman WR et al. First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer. Cancer Chemother Pharmacol 2012; 69: 733-41.
74. Lock RB, Carol H, Morton CL et al. Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program. Pediatr Blood Cancer 2012; 58: 916-23.
75. Ding X, Yan F, Yao P et al. Probing CENP-E function in chromosome dynamics using small molecule inhibitor syntelin. Cell Res 2010; 20: 1386-9.
76. Komlodi-Pasztor E, Sackett D, Wilkerson J, Fojo T. Mitosis is not a key target of microtubule agents in patient tumors. Nat Rev Clin Oncol 2011; 8: 244-50.
77. Komlodi-Pasztor E, Sackett DL, Fojo AT. Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale. Clin Cancer Res 2012; 18: 51-63.
78. Liu M, Aneja R, Liu C et al. Inhibition of the mitotic kinesin Eg5 up-regulates Hsp70 through the phosphatidylinositol 3-kinase/Akt pathway in multiple myeloma cells. J Biol Chem 2006; 281: 18090-7.
79. Jaattela M, Wissing D, Kokholm K, Kallunki T, Egeblad M. Hsp70 exerts its anti-apoptotic function downstream of caspase-3-like proteases. EMBO J 1998; 17: 6124-34.
80. Liu X, Cao X, Wei R et al. Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL. Cancer Gene Ther 2012; 19: 49-57.
81. Huang Y, Yao Y, Xu HZ, Wang ZG, Lu L, Dai W. Defects in chromosome congression and mitotic progression in KIF18A-deficient cells are partly mediated through impaired functions of CENP-E. Cell Cycle 2009; 8: 2643-9.